Biotech | April 06, 2026
Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial
Safety was equally impressive. ENV-294 was well tolerated
Safety was equally impressive. ENV-294 was well tolerated
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Subscribe To Our Newsletter & Stay Updated
